- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Clene Inc. (CLNN)
The Clene share price today is 6.7000, view NASDAQ CLNN stock exchange data. Track the latest Clene share price with real-time updates on CLNN stock performance including market cap, day range, 52-week range and dividend yield. Access CLNN charts, earnings dates and analyst estimates to support your investment decisions.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.5500
6.9000
52 wk Range
2.3600
13.5000
CLNN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.55006.9000
52 wk Range
2.360013.5000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CLNN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
30.6667
Upside
+357.71%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
- Ugwumba Chidozie sells $604,129 in Clene Inc. stock
- Investing.com
- Form 8K Clene Inc. For: 22 May
- Investing.com
- Form 13G Clene Inc. For: 12 May
- Investing.com
- Form 13G Clene Inc. For: 15 May
- Investing.com
- Form 8K Clene Inc. For: 22 May
- Investing.com
- Form 13G Clene Inc. For: 15 May
- Investing.com
- Form 13G Clene Inc. For: 14 May
- Investing.com
- Form 8K Clene Inc. For: 14 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 30.6667
(+357.71% Upside)
Earnings
Latest Release
14-05-2026
EPS / Forecast
-0.69 / -0.46
Revenue / Forecast
15K / --
Compare CLNN to Peers and Sector
Metrics to compare | CLNN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLNNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.6x | −3.3x | −0.5x | |
PEG Ratio | −0.15 | −0.07 | 0.00 | |
Price/Book | −4.6x | 2.5x | 2.6x | |
Price / LTM Sales | 638.9x | 254.0x | 3.1x | |
Upside (Analyst Target) | 347.8% | 222.4% | 52.5% | |
Fair Value Upside | Unlock | −5.3% | 6.0% | Unlock |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company’s lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Clene (CLNN) Share Price Today?
The Clene share price today is 6.7000.
What is the current Clene (CLNN) share price and day range?
As of 26-05-2026, the Clene share price is 6.7000, with a previous close of 6.7000. The share price has ranged from 6.5500 to 6.9000 today, while the 52-week range spans from 2.3600 to 13.5000.
What Is the Clene Market Cap?
As of today, Clene market cap is 85.6100M.
What Is the Clene (CLNN) Share Price Target?
The average 12-month share price target for Clene is 30.6667, with a high estimate of 50 and a low estimate of 20. 6 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +357.71% Upside potential.
What Is Clene's Earnings Per Share (TTM)?
The Clene EPS (TTM) is -3.1724.
When Is the Next Clene Earnings Date?
Clene will release its next earnings report on 17-08-2026.
From a Technical Analysis Perspective, Is CLNN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does Clene Trade On?
Clene is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Clene?
The stock symbol for Clene is "CLNN."
How Many Times Has Clene Stock Split?
Clene has split 1 times.
How Many Employees Does Clene Have?
Clene has 78 employees.
What Is the CLNN Premarket Price?
CLNN's last pre-market stock price is 6.7700. The pre-market share volume is 1,130.0000, and the stock has changed by 0.0700, or 1.0400%.
What Is the CLNN After Hours Price?
CLNN's last after hours stock price is 6.5600, the stock has changed by -0.1400, or -2.0900%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.